公开(公告)号：US20200291106A1

公开(公告)日：2020-09-17

申请号：US16682773

申请日：2019-11-13

Applicant: Genentech, Inc.

Inventor： Sek Chung FUNG ,  Matthew MOYLE ,  Mason LU ,  Changning YAN ,  Sanjaya SINGH ,  Dan HUANG

IPC: C07K16/24

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

公开(公告)号：US20180251538A1

公开(公告)日：2018-09-06

申请号：US15721570

申请日：2017-09-29

Applicant: GENENTECH, INC.

Inventor： Sek Chung FUNG ,  Matthew MOYLE ,  Mason LU ,  Changning YAN ,  Sanjaya SINGH ,  Dan Huang

IPC: C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.